Eli Lilly's weight-loss drug succeeds in trials with sleep apnea patients [Reuters]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Reuters
, opens new tab weight-loss drug succeeded in two late-stage trials testing it in patients with obstructive sleep apnea, the company said on Wednesday. The drug, chemically known as tirzepatide, helped cut the frequency of irregular breathing by as much as 63% on average across the two trials in patients with the condition. Lilly said the drug's safety profile was similar to that observed in previous studies. Weight-loss drugs such as Lilly's Zepbound and Novo Nordisk's (NOVOb.CO) New Tab , opens new tab Wegovy, called GLP-1 agonists, have already brought in billions of dollars in sales as treatments for obesity and diabetes. Lilly's trial results add to a growing body of clinical evidence that suggests GLP-1 drugs have medical benefits beyond diabetes and weight loss. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. Reporting by Bhanvi Satija in Bengaluru; Editing by Sriraj Kalluvila and Shinji
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Lilly Raises 2024 Guidance as Zepbound Keeps Flying Off Shelves [BNN Bloomberg (Canada)]BNN Bloomberg
- Chasing Novo and Lilly: The obesity drugs that could challenge Wegovy and Zepbound [Yahoo! Finance]Yahoo! Finance
- How expanded use of GLP-1s could affect long-term outlooks for Eli Lilly and Novo Nordisk [Yahoo! Finance]Yahoo! Finance
- Should You Invest in Novo Nordisk (NVO) Ahead of Q1 Earnings? [Yahoo! Finance]Yahoo! Finance
- UPDATE 1-One dose of Novo Nordisk's Wegovy back in supply, FDA website shows [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/3/23 - Beat
NVO
Sec Filings
- 4/26/24 - Form 6-K
- 4/25/24 - Form 6-K
- 4/25/24 - Form 6-K
- NVO's page on the SEC website